vTv Therapeutics
VTVT
29 hedge funds and large institutions have $6.55M invested in vTv Therapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 10 closing their positions.
17% more capital invested
Capital invested by funds: $5.58M → $6.55M (+$963K)
0.1% more ownership
Funds ownership: 0.14% → 0.24% (+0.1%)
6% less funds holding
Funds holding: 31 → 29 (-2)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$2.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.12M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$940K |
| 4 |
Morgan Stanley
New York
|
+$172K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAG
Winthrop Advisory Group
Boston,
Massachusetts
|
-$409K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$177K |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
-$123K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$63K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$47.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | -$1.29K | -24 | -44% |
|
|
PA
27
Parallel Advisors
San Francisco,
California
| $1K | – | – | – |
|
28
BNP Paribas Financial Markets
Paris,
France
| $793 | -$161 | -3 | -13% |
|
|
GCP
29
GSA Capital Partners
London,
United Kingdom
| – | -$177K | -2,887 | Closed |
|
|
30
Vontobel Holding
Zurich,
Switzerland
| – | -$123K | -2,000 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$63K | -1,021 | Closed |
|
32
Goldman Sachs
New York
| – | -$37K | -603 | Closed |
|
33
Marshall Wace
London,
United Kingdom
| – | -$36K | -585 | Closed |
|
|
GPFA
34
Game Plan Financial Advisors
Westlake,
Ohio
| – | -$20K | -325 | Closed |
|
|
CSS
35
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$17K | -277 | Closed |
|
|
WAG
36
Winthrop Advisory Group
Boston,
Massachusetts
| – | -$409K | -76 | Closed |
|
37
Barclays
London,
United Kingdom
| – | -$2K | -38 | Closed |
|
38
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$54 | +1 | +25% |
|
VTVT Hedge Fund Activity: Q4 2021 in Review
29 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2021, worth a combined $6.55M — up 17% from $5.58M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of VTVT and 8 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Samsara BioCapital, opening a new position worth an estimated $2.2M. The largest seller was Winthrop Advisory Group, exiting entirely with an estimated $409K sold.
- 29 institutional investors held vTv Therapeutics (VTVT) as of Q4 2021, down from 31 in Q3 2021.
- Funds reported $6.55M of vTv Therapeutics stock for Q4 2021, up 17% quarter-over-quarter.
- 8 funds opened new vTv Therapeutics positions in Q4 2021 and 10 closed out, a net change of -2 holders.
- The largest vTv Therapeutics buyer in Q4 2021 was Samsara BioCapital, an estimated $2.2M added.
- The largest vTv Therapeutics seller in Q4 2021 was Winthrop Advisory Group, an estimated $409K sold.
Based on aggregated 13F filings for Q4 2021.